Fast Market Research announces the availability of the new Business Monitor International report, "Oman Pharmaceuticals & Healthcare Report Q1 2016", on their comprehensive research portal

Boston, MA -- (SBWire) -- 01/06/2016 --Despite being among the smallest pharmaceutical and healthcare markets in the GCC, Oman's ambitious expansion projects will attract investments from numerous international players. Engagement of the private sector will provide the most significant growth prospects, although the public sector will still remain the dominant healthcare payer.

Headline Expenditure Projections

Pharmaceuticals: OMR205mn (USD532mn) in 2014 to OMR219mn (USD568mn) in 2015; 6.8% in local currency and US dollar terms. Forecast in line with Q 3 15.

Healthcare: OMR855mn (USD2.22bn) in 2014 to OMR942mn (USD2.45bn) in 2015; +10.1% in local currency and US dollar terms. Forecast in line with Q 3 15.

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q415, Oman scores 49.0 out of 100 in the BMI Pharmaceutical Risk/Reward Index, which has seen the move up one position to ninth place in the Middle East and Africa matrix out of 31 countries.

Get More Details on this Report and a Full Table of Contents at Oman Pharmaceuticals & Healthcare Report Q1 2016

Key Trends And Developments

In September 2015, Oman's Ministry of Health will be organizing the fifth installment of the Oman Health Exhibition and Conference to encourage drugmakers to establish bases in the country.

Oman's medical insurance sector witnessed growth of 32% to OMR63.07mn (USD163.9mn) in the first half of 2015, according to insurance market watchdog Capital Market Authority in August 2015.

From July 1 2015, the prices of 1,180 prescription medicines were reduced at private pharmacies as part of the second stage of the drug price review conducted by the Directorate General of Pharmaceutical Affairs and Drug Control at the Ministry of Health.

BMI Economic View

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits
-Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
-Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
-Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI?s forecast analysis, and taken together with BMI?s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

-Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ?000 population).
-Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
-Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
-Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
-OTC Drug Market: OTC sales (USDbn & % of total sales).
-Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI?s Pharmaceuticals and Healthcare Risk Reward Index

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

-Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2016
-Kenya Pharmaceuticals & Healthcare Report Q1 2016
-Ukraine Pharmaceuticals & Healthcare Report Q1 2016
-Thailand Pharmaceuticals & Healthcare Report Q1 2016
-Peru Pharmaceuticals & Healthcare Report Q1 2016